FCM
ACAD icon

Frontier Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Frontier Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-823,586
Closed -$25.8M – 270
2023
Q4 		$25.8M Buy
823,586
+65,973
+9% +$1.58M 0.26% 137
2023
Q3 		$15.8M Buy
757,613
+107,903
+17% +$2.93M 0.17% 166
2023
Q2 		$15.6M Buy
649,710
+115,655
+22% +$2.57M 0.15% 170
2023
Q1 		$10.1M Buy
534,055
+173,178
+48% +$3.3M 0.1% 194
2022
Q4 		$5.75M Sell
360,877
-123,686
-26% -$1.93M 0.06% 225
2022
Q3 		$7.93M Sell
484,563
-81,760
-14% -$1.32M 0.09% 213
2022
Q2 		$7.98M Sell
566,323
-312,667
-36% -$5.84M 0.09% 220
2022
Q1 		$21.3M Sell
878,990
-177,723
-17% -$4.3M 0.19% 163
2021
Q4 		$24.7M Buy
1,056,713
+667,144
+171% +$13.4M 0.2% 157
2021
Q3 		$6.47M Sell
389,569
-657,778
-63% -$12.7M 0.05% 243
2021
Q2 		$25.5M Buy
1,047,347
+585,970
+127% +$13.2M 0.19% 168
2021
Q1 		$11.9M Sell
461,377
-497,315
-52% -$21.9M 0.09% 211
2020
Q4 		$51.3M Sell
958,692
-35,347
-4% -$1.75M 0.38% 96
2020
Q3 		$41M Sell
994,039
-192,445
-16% -$8.31M 0.36% 103
2020
Q2 		$57.5M Sell
1,186,484
-168,971
-12% -$8.11M 0.51% 67
2020
Q1 		$57.3M Buy
+1,355,455
New +$55.8M 0.64% 53
2018
Q2 		– Sell
-289,443
Closed -$6.5M – 299
2018
Q1 		$6.5M Buy
289,443
+201,709
+230% +$5.58M 0.05% 260
2017
Q4 		$2.64M Sell
87,734
-318,787
-78% -$10.2M 0.02% 276
2017
Q3 		$15.3M Sell
406,521
-265,188
-39% -$8.63M 0.11% 214
2017
Q2 		$18.7M Buy
671,709
+36,021
+6% +$1.07M 0.14% 199
2017
Q1 		$21.9M Buy
635,688
+260,815
+70% +$9.21M 0.16% 189
2016
Q4 		$10.8M Sell
374,873
-258,817
-41% -$6.85M 0.08% 234
2016
Q3 		$20.2M Buy
633,690
+362,459
+134% +$12.3M 0.16% 182
2016
Q2 		$8.8M Sell
271,231
-10,968
-4% -$367K 0.07% 245
2016
Q1 		$7.89M Sell
282,199
-63,185
-18% -$1.38M 0.06% 253
2015
Q4 		$12.3M Buy
+345,384
New +$12.2M 0.1% 232

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Frontier Capital Management's ACAD Position: Q1 2024 in Review

Frontier Capital Management sold out of Acadia Pharmaceuticals (ACAD) in Q1 2024, closing a stake of 823,586 shares — an estimated $25.8M sold.

Frontier Capital Management first reported a position in ACAD in Q4 2015 and held it in 26 quarters. The position peaked at $57.5M in Q2 2020. 267 funds tracked by Wall St. Rank hold ACAD as of Q1 2024.

  • Frontier Capital Management reported no remaining Acadia Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Frontier Capital Management sold 823,586 Acadia Pharmaceuticals shares in Q1 2024, an estimated $25.8M.
  • Frontier Capital Management first reported a position in Acadia Pharmaceuticals in Q4 2015 and held it in 26 quarters.
  • Frontier Capital Management's Acadia Pharmaceuticals position peaked at $57.5M in Q2 2020.
  • 267 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2024.

Based on Frontier Capital Management's 13F filing for Q1 2024, filed 15 May 2024.